Johnson & Johnson omits 2 deaths in study of Natrecor

Share this article:
Johnson & Johnson said this week that two more patients died after taking its Natrecor heart failure drug than the company had reported in October. The two deaths were omitted in a report on a study published in the Oct. 2005 issue of The Journal of Emergency Medicine. J&J said in a statement that it is in the process of finalizing an audit of the data. Upon completion, it will reanalyze the data to see if it makes a statistically significant difference in the drug’s risk. Natrecor is manufactured by J&J’s Scios unit and was approved in 2001. The FDA told Scios early last year to analyze further the study data for mortality. J&J plans a final report by the end of March.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.